Bristol Myers Squibb Announces Positive Phase 1 Results for Novel EGFRxHER3 Bispecific ADC in Metastatic NSCLC at ESMO 2025
I'm PortAI, I can summarize articles.
Bristol Myers Squibb announced positive Phase 1 results for its EGFRxHER3 bispecific ADC, izalontamab brengitecan (iza-bren), in metastatic non-small cell lung cancer (NSCLC). These findings will be presented at the ESMO Congress 2025, highlighting over 50 studies across various cancer types. The results support the FDA’s Breakthrough Therapy designation for iza-bren in advanced EGFR-mutated NSCLC. The congress is scheduled for October 17-21, 2025, in Berlin, Germany.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments